About
Bernard Gilly is CEO of BrainEver, a biopharmaceutical company developing therapeutic solutions for age-related neurodegenerative diseases including ALS and Parkinson's disease, with preclinical studies planned to advance to clinical trials by 2025. He is also president of Ibionext, an investment fund founded in 2012 that backs biotech and medtech companies. His background includes co-founding Gensight Biologics and Fovea Pharmaceuticals (sold to Sanofi for €370 million), serving as president and CEO of Transgene during its public listing on Euronext and Nasdaq in 1998, and working as a partner at Sofinnova Partners from 2000 to 2005.
Experience
- BrainEverCEOcurrent2015 — presentParis
- iBionextChairmancurrent2015 — present
- GenSight BiologicsCEO2013 — 2024
- Fovea Pharmaceuticals / SanofiCEO2005 — 2012
- Sofinnova PartnersPartner2000 — 2005
- TransgeneCEO1992 — 2000
- PMC / Sanofi PasteurVP R&D1987 — 1994
Skills & more
Languages Anglais · Français
From Bernard's professional profile.
Shared employers
Also worked at BrainEver1
Also worked at Sofinnova Partners44
Anne HorganPartner at Cambridge Innovation CapitalLaetitia SchwabPrincipal at SR One Capital ManagementAntoine Papiernik PapiernikChairman and Managing Partner at Sofinnova PartnersGraziano SeghezziManaging Partner at Sofinnova PartnersMichael KrelPartner at Sofinnova PartnersHenrijette RichterManaging Partner at Sofinnova Partners
+ 38 more
Also worked at Transgene1
Also worked at PMC / Sanofi Pasteur84
Christine AylwardFounder & Managing Partner at Magnetic VenturesAlan WaltsVenture Partner at Advent Life SciencesMatt VineSenior Associate at RRE VenturesWalter OlesiakOperating Partner at RDiscoveryRamy RiadPresident, Plasma-Derived Therapies Business Unit at Takeda VenturesCarlos Garcia-EcheverriaVenture Partner at Ysios Capital
)
+ 78 more
